Summit Therapeutics PLC (LSE:SUMM) - Share price - Overview

Stock Report

Summit Therapeutics PLC SUMM

Last Price
GBX184.25

Day Change
9.25|5.29%

As of 23/06/2017
09:17:14 BST | GBX
Minimum 15 Minutes Delay.

Last Close175.00p
Day Range172.51 - 184.25
Mkt Cap108.30Mil
52-Wk Range88.00 - 262.00
Yield %0.00
ISINGB00BN40HZ01
Volume1,890
P/E-5.26
P/S49.23
P/CF9.33

Share Price

Total Returns 22/06/2017

 Chg (%)  
More ...
Summit Therapeutics PLC-1.41 
FTSE 100 TR GBP-0.45
 
Financials
201520162017
More ...
Income Statement
Turnover0.000.002.30
Operating Profit-12.71-20.18-24.85
Net Profit-11.36-17.09-21.37
Reported EPS-29.00-29.00-35.00
Balance Sheet
Current Assets15.1920.8633.34
Non Current Assets4.204.224.25
Total Assets19.4025.0837.59
Current Liabilities3.773.2110.90
Total Liabilities4.433.9441.08
Total Equity14.9721.13-3.49
Cash Flow
Operating Cash Flow-11.98-18.589.14
Net Change in Cash9.244.9212.47
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
201811.7522.99-7.61---
201912.0117.22-25.1310.17-0.40--

Company Profile

Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

Sector

Drug Manufacturers - Specialty & Generic

Market Position

890 of 1843 Companies

Index

FTSE AIM All Share

Outlook

(14/06/2017) no outlook statement

Next Event 18/07/2017

Next AGM
Ratios
CompSecMkt
More ...
PER (E)8.4315.7216.88
Div Yld (E)0.003.494.13
PEG (E)0.000.471.19
ROCE2,348.30191.21209.80
Op Mrgn-1,078.69-3.75-99.88
EPS Grwth0.0045.5133.48
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Frank Armstrong
Chief Executive OfficerMr. Glyn Edwards
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.